Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis
Al-Bazaz M, Alsdorf W, Leypoldt L, Sonnemann P, Schaefers C, Artzenroth J, Harzer M, Kamili A, Bartke L, Cords L, Vorwerk J, Leitner T, Maulhardt M, Brinkert K, Brioli A, Richardson T, Holtick U, Hillmann S, Salwender H, Khandanpour C, Bokemeyer C, Weisel K, Kosch R
AM J HEMATOL. 2026;101(7):1433-1439.

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience
Artzenroth J, Kosch R, Al-Bazaz M, Bartke L, Cords L, Güsmer C, Harzer M, Heinrich F, Kamili A, Leypoldt L, Madanchi R, Monin M, Schaefers C, Schlemmer T, Seibel J, Bokemeyer C, Weisel K, Alsdorf W
TRANSPL CELL THER. 2026 [Epub ahead of print].

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis
Harzer M, Gross-Fengels N, Melzer F, Molwitz I, Kosch R, Al-Bazaz M, Artzenroth J, Cords L, Bartke L, Kamili A, Alsdorf W, Bokemeyer C, Weisel K, Leypoldt L, Schaefers C
ANN HEMATOL. 2026;105(7):.

Letzte Aktualisierung aus dem FIS: 16.09.2026 - 01:42 Uhr